Search Results - "Mittra, Erik S"

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816 by Press, Oliver W, Li, Hongli, Schöder, Heiko, Straus, David J, Moskowitz, Craig H, LeBlanc, Michael, Rimsza, Lisa M, Bartlett, Nancy L, Evens, Andrew M, Mittra, Erik S, LaCasce, Ann S, Sweetenham, John W, Barr, Paul M, Fanale, Michelle A, Knopp, Michael V, Noy, Ariela, Hsi, Eric D, Cook, James R, Lechowicz, Mary Jo, Gascoyne, Randy D, Leonard, John P, Kahl, Brad S, Cheson, Bruce D, Fisher, Richard I, Friedberg, Jonathan W

“…Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and…”
Get full text

Establishing a robust radioligand therapy program: A practical approach for North American centers by Mittra, Erik S., Wong, Rebecca K. S., Winters, Celeste, Brown, Adam, Murley, Shondra, Kennecke, Hagen

“…Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including…”
Get full text

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies by Mittra, Erik S, Koglin, Norman, Mosci, Camila, Kumar, Meena, Hoehne, Aileen, Keu, Khun Visith, Iagaru, Andrei H, Mueller, Andre, Berndt, Mathias, Bullich, Santiago, Friebe, Matthias, Schmitt-Willich, Heribert, Gekeler, Volker, Fels, Lüder M, Bacher-Stier, Claudia, Moon, Dae Hyuk, Chin, Frederick T, Stephens, Andrew W, Dinkelborg, Ludger M, Gambhir, Sanjiv S

“…(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a novel radiopharmaceutical for Positron Emission Tomography (PET) imaging. It is a glutamate…”
Get full text

Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma by Park, Sonya Y., Mosci, Camila, Kumar, Meena, Wardak, Mirwais, Koglin, Norman, Bullich, Santiago, Mueller, Andre, Berndt, Mathias, Stephens, Andrew W., Chin, Frederick T., Gambhir, Sanjiv S., Mittra, Erik S.

“…Purpose (4 S )-4-(3-[ 18 F]Fluoropropyl)- l -glutamic acid ([ 18 F]FSPG) measures system x C − transporter activity and shows promise for oncologic imaging. We…”
Get full text

Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI by MITTRA, Erik S, FAN-MINOGUE, Hua, LIN, Frank I, KARAMCHANDANI, Jason, SRIRAM, Venkataraman, HAN, May, GAMBHIR, Sanjiv S

“…Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent…”
Get full text

Neuroendocrine Tumor Therapy: 177 Lu-DOTATATE by Mittra, Erik S

“…The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to…”
Get full text

Comparative morphometrics of the primate apical tuft by Mittra, Erik S., Smith, Heather F., Lemelin, Pierre, Jungers, William L.

“…The relationship between the structure and function of the primate apical tuft is poorly understood. This study addresses several hypotheses about apical tuft…”
Get full text

SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors by Hope, Thomas A, Allen-Auerbach, Martin, Bodei, Lisa, Calais, Jeremie, Dahlbom, Magnus, Dunnwald, Lisa K, Graham, Michael M, Jacene, Heather A, Heath, Courtney Lawhn, Mittra, Erik S, Wright, Chadwick L, Fendler, Wolfgang P, Herrmann, Ken, Taïeb, David, Kjaer, Andreas

Get full text

The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors by Raymond, Lauren M, Korzun, Tetiana, Kardosh, Adel, Kolbeck, Kenneth J, Pommier, Rodney, Mittra, Erik S

“…Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the…”
Get more information

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline by Del Rivero, Jaydira, Perez, Kimberly, Kennedy, Erin B, Mittra, Erik S, Vijayvergia, Namrata, Arshad, Junaid, Basu, Sandip, Chauhan, Aman, Dasari, Arvind N, Bellizzi, Andrew M, Gangi, Alexandra, Grady, Erin, Howe, James R, Ivanidze, Jana, Lewis, Mark, Mailman, Josh, Raj, Nitya, Soares, Heloisa P, Soulen, Michael C, White, Sarah B, Chan, Jennifer A, Kunz, Pamela L, Singh, Simron, Halfdanarson, Thorvardur R, Strosberg, Jonathan R, Bergsland, Emily K

“…To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors…”
Get full text

Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors by Naraev, Boris G., Mailman, Josh, Halfdanarson, Thorvardur R., Soares, Heloisa P., Mittra, Erik S., Hallet, Julie

“…Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a complex and heterogenous family of solid malignancies that originate from neuroendocrine tissue…”
Get full text

Clinical Evaluation of (4S)-4-(3-[ 18 F]Fluoropropyl)-L-glutamate ( 18 F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer by Park, Sonya Youngju, Na, Sae Jung, Kumar, Meena, Mosci, Camila, Wardak, Mirwais, Koglin, Norman, Bullich, Santiago, Mueller, Andre, Berndt, Mathias, Stephens, Andrew W, Cho, Yong Mee, Ahn, Hanjong, Chae, Sun Young, Kim, Hye Ok, Moon, Dae Hyuk, Gambhir, Sanjiv S, Mittra, Erik S

“…(4S)-4-(3-[ F]Fluoropropyl)- -glutamic acid ( F-FSPG) is a radiopharmaceutical for PET imaging of system x activity, which can be upregulated in prostate…”
Get full text

18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors by Wardak, Mirwais, Sonni, Ida, Fan, Audrey P, Minamimoto, Ryogo, Jamali, Mehran, Hatami, Negin, Zaharchuk, Greg, Fischbein, Nancy, Nagpal, Seema, Li, Gordon, Koglin, Norman, Berndt, Mathias, Bullich, Santiago, Stephens, Andrew W, Dinkelborg, Ludger M, Abel, Ty, Manning, H Charles, Rosenberg, Jarrett, Chin, Frederick T, Gambhir, Sanjiv Sam, Mittra, Erik S

Get full text

18 F-FSPG PET/CT Imaging of System x C - Transporter Activity in Patients with Primary and Metastatic Brain Tumors by Wardak, Mirwais, Sonni, Ida, Fan, Audrey P, Minamimoto, Ryogo, Jamali, Mehran, Hatami, Negin, Zaharchuk, Greg, Fischbein, Nancy, Nagpal, Seema, Li, Gordon, Koglin, Norman, Berndt, Mathias, Bullich, Santiago, Stephens, Andrew W, Dinkelborg, Ludger M, Abel, Ty, Manning, H Charles, Rosenberg, Jarrett, Chin, Frederick T, Gambhir, Sanjiv Sam, Mittra, Erik S

“…Background The PET tracer (4S)-4-(3-[ F]fluoropropyl)-l-glutamate ( F-FSPG) targets the system x cotransporter, which is overexpressed in various tumors…”
Get full text

Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for Imaging xC― Transporter Using Positron Emission Tomography in Patients with Non―Small Cell Lung or Breast Cancer by BAEK, Sora, CHOI, Chang-Min, HULTSCH, Christina, SCHATZ, Christoph A, DINKELBORG, Ludger M, MITTRA, Erik S, GAMBHIR, Sanjiv S, DAE HYUK MOON, SEI HYUN AHN, JONG WON LEE, GONG, Gyungyub, RYU, Jin-Sook, SEUNG JUN OH, BACHER-STIER, Claudia, FELS, Luder, KOGLIN, Norman

“…(4S)-4-(3-[(18)F]fluoropropyl)-l-glutamate (BAY 94-9392, alias [(18)F]FSPG) is a new tracer to image x(C)(-) transporter activity with positron emission…”
Get full text

Characterization of Physiologic (18)F FSPG Uptake in Healthy Volunteers by Mosci, Camila, Kumar, Meena, Smolarz, Kamilla, Koglin, Norman, Stephens, Andrew W, Schwaiger, Markus, Gambhir, Sanjiv S, Mittra, Erik S

“…Purpose To evaluate the normal biodistribution and kinetics of (S)-4-(3-[18F]fluoropropyl)-l-glutamic acid ((18)F FSPG) in healthy volunteers and to compare…”
Get full text

Clinical [18F]FSPG Positron Emission Tomography Imaging Reveals Heterogeneity in Tumor-Associated System xc− Activity by Sharkey, Amy R., Koglin, Norman, Mittra, Erik S., Han, Sangwon, Cook, Gary J. R., Witney, Timothy H.

“…Background: (4S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) positron emission tomography/computed tomography (PET/CT) provides a readout of system xc−…”
Get full text

Standard OSEM vs. regularized PET image reconstruction: qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals by Lantos, Judit, Mittra, Erik S, Levin, Craig S, Iagaru, Andrei

“…We investigated the block sequential regularized expectation maximization (BSREM) algorithm. ACR phantom measurements with different count statistics and 60…”
Get full text

Case 207: Hodgkin lymphoma with paraneoplastic hypercalcemic pancreatitis by Mittra, Erik S, Davidzon, Guido

“…A 15-year-old girl presented with a 2-month history of 30-lb (13.6 kg) weight loss, chest and abdominal pain, nausea, bilious emesis, cough, and shortness of…”
Get full text

Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors by Moradi, Farshad, Jamali, Mehran, Barkhodari, Amir, Schneider, Bernadette, Chin, Frederick, Quon, Andrew, Mittra, Erik S, Iagaru, Andrei

“…PURPOSETo analyze the biodistribution of Ga-DOTA-TATE in the normal tissues and uptake in benign, indeterminate, and malignant lesions in a population of…”
Get full text